Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors), GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Infectious DiseasesOtorhinolaryngologic DiseasesRespiratory Diseases+ [2]

Active Indication

Acute otitis externaBone and joint infectionsInfectious Diseases+ [2]

Inactive Indication-

Originator Organization

Novartis Pharma AG

Active Organization

Sandoz, Inc.Novartis Pharmaceuticals Australia Pty Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

United States (10 Feb 1998),

Bone and joint infectionsInfectious DiseasesLower Respiratory Tract Infections+ [1]

Regulation-

Structure/Sequence

Molecular FormulaC21H30O5

InChIKeyJYGXADMDTFJGBT-VWUMJDOOSA-N

CAS Registry50-23-7

View All Structures (2)

100 Clinical Results associated with Ciprofloxacin Hydrochloride/Hydrocortisone

100 Translational Medicine associated with Ciprofloxacin Hydrochloride/Hydrocortisone

100 Patents (Medical) associated with Ciprofloxacin Hydrochloride/Hydrocortisone

Literatures (Medical) associated with Ciprofloxacin Hydrochloride/Hydrocortisone

01 Aug 2017·The LaryngoscopeQ1 · MEDICINE

Price variation in the most commonly prescribed ear drops in Southern California

Q1 · MEDICINE

Article

Author: Ghavami, Yaser ; Moshtaghi, Omid ; Gu, Jeff ; Lin, Harrison W. ; Huang, Melissa ; Djalilian, Hamid R. ; Moshtaghi, Afsheen ; Haidar, Yarah M. ; Sahyouni, Ronald

Objectives/HypothesisTo evaluate the variability and discrepancies among the most commonly prescribed ear drops sold at pharmacies in southern California.Study DesignProspective study evaluating 11 commonly used ear drops to treat otologic disorders.MethodsRandomly selected drug stores in three major counties in Southern California (Los Angeles, Orange, and San Diego) were included. Mean, range, minimum, and maximum prices for each drug were calculated and analyzed. The median income of pharmacy ZIP code was also cross‐referenced.ResultsData were collected from 108 pharmacies. The mean prices are noted for each of the individual drugs: Cortisporin (brand) 10 mL, $82.70; neomycin, polymyxin B sulfates, and hydrocortisone (Cortisporin–generic) 10 mL, $34.70; ofloxacin (generic) 10 mL, $99.95; sulfacetamide (generic) 15 mL, $40.18; Ciprodex (brand) 7.5 mL, $194.44; Cipro HC (brand) 10 mL, $233.32; Vosol (brand) 15 mL, $120.75; acetic acid (Vosol–generic) 10 mL, $116.55; VosolHC (brand) 10 mL, $204.14; acetic acid/aluminum acetate (Domeboro–generic) 60 mL, $22.91; and Tobradex (brand) 5 mL, $166.47.ConclusionsThere is significant variability among the prices of ear drops across Southern Californian pharmacies, which can be a financial burden to patients paying out of pocket or with high deductibles. A state‐mandated, publically accessible report of drug prices may help decrease variability and cost by promoting competition among pharmacies. Price negotiations by governmental payers may assist in reducing prices. In the treatment of otologic disorders, clinicians can help reduce costs for patients by prescribing generic ear drop medications and cheaper alternatives when clinically appropriate.Level of Evidence4. Laryngoscope, 127:1780–1784, 2017

01 Sep 2008·Journal of Clinical Pediatric DentistryQ4 · MEDICINE

Effects Of Antibacterial Agents On Dental Pulps Of Monkeys Mechanically Exposed And Contaminated.

Q4 · MEDICINE

Article

Author: Jurado, R ; Vieira, A ; Cannon, M ; Cernigliaro, J ; Percinoto, C

Objective: The purpose of this study was to compare the effectiveness of antibacterial agents and mineral trioxide aggregate in the healing of bacterial contaminated primate pulps. Study Design: The experiment required four adult male primates (Cebus opella) with 48 teeth prepared with buccal penetrations into the pulpal tissues. The preparations were performed under general anesthesia and the exposed pulps were exposed to cotton pellets soaked in a bacterial mixture consisting of microorganisms normally found in human pulpal abscesses obtained from the Endodontic Clinic of UNESP. Following bacterial inoculation (30 minute exposure), the pulpal tissue was immediately treated with either sterile saline, Cipro HC Otic solution(12), diluted Buckley' formecresol solution (12) or Otosporin otic solution (12) for 5 minutes. After removal of the pellet, hemostasis was obtained and a ZOE base applied to the DFC treated pulps and the non-treated controls (12). After hemostasis, the other exposed pulps were covered with mineral trioxide aggregate (ProRoot). The pulpal bases were all covered with a RMGI (Fuji II LC). The tissue samples were collected at one day, two days, one week and over four weeks (34 days). Results: Following perfusion fixation,the samples were demineralized, sectioned, stained and histologically graded. After histologic analysis,presence of neutrophilic infiltrate and areas of hemorrhage with hyperemia were observed. The depth of the neutrophilic infiltrate depended on the agent or material used. The pulpal tissue treated with Otic suspensions demonstrated significantly less inflammation (Kruskal Wallis non parametric analysis, H=9.595 with 1 degree of freedom; P=0.0223) than the formocresol and control groups. The hard tissue bridges formed over the exposure sites were more organized in the MTA treatment groups than in the control and ZOE groups (Kruskal Wallis non parametric analysis, H=18.291 with 1 degree of freedom; P=0.0004).Conclusions: Otic suspensions and MTA are effective in treating bacterial infected pulps and stimulate the production of a hard tissue bridge over the site of the exposure.

01 Jul 2008·American Journal of OtolaryngologyQ3 · MEDICINE

A single topical agent is clinically equivalent to the combination of topical and oral antibiotic treatment for otitis externa

Q3 · MEDICINE

Article

Author: Reynaldo L. Makabale ; Barbara P. Belcher ; G. Michael Wall ; Peter J. Conroy ; Robert Bettis ; Peter S. Roland ; Susan Potts ; Gail Hogg ; Sheryl Dupre ; Kaye Weber

OBJECTIVETo demonstrate clinical equivalence (statistical noninferiority) of topical ciprofloxacin and hydrocortisone (CHC, Cipro HC) and topical neomycin/polymyxin b/hydrocortisone (NPH, Cortisporin) with systemic amoxicillin (AMX, Amoxil), for treatment of acute otitis externa (AOE).DESIGNRandomized, active-control, observer-blind, multicenter trial.PATIENTSAltogether, 206 patients were enrolled (CHC, 106; NPH + AMX, 100). Patients were > or =1 year of age, had AOE >2 days with at least mild symptoms, and gave informed consent. All were evaluable for safety, and 151 were evaluable for efficacy.INTERVENTIONSCiprofloxacin and hydrocortisone 3 drops twice daily for 7 days (adults and children) or NPH 4 drops (adults) or 2 drops (children) with AMX 250 mg (adults and children) 3 times daily for 10 days, as directed in approved product labeling.MAIN OUTCOME MEASURESThe primary efficacy variable was response to therapy 7 days after treatment ended (test of cure). Secondary variables included time to end of pain, symptom scores (otalgia and tenderness) and microbiological eradication. Noninferiority was declared if the lower confidence limit around the measurement difference was above -10 (nearer zero).RESULTSResponse to therapy was higher for CHC (95.71% vs 89.83%) but was statistically noninferior (lower confidence limit, -4.98) to NPH + AMX. Median time to end of pain was 6 days for both groups. Noninferiority was declared for symptom scores at all measurement periods and for microbiological eradication. No serious adverse events related to treatment were reported.CONCLUSIONSCiprofloxacin and hydrocortisone is clinically equivalent to NPH + AMX for the treatment of AOE in adults and children. However, low systemic exposure, absence of ototoxicity, and less frequent dosing clearly favor Cipro HC.

100 Deals associated with Ciprofloxacin Hydrochloride/Hydrocortisone

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	S02CA03 S03CA04 S01CA03	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute otitis externa	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	12 Mar 2008
Bone and joint infections	United States	Sandoz, Inc.	10 Feb 1998
Infectious Diseases	United States	Sandoz, Inc.	10 Feb 1998
Lower Respiratory Tract Infections	United States	Sandoz, Inc.	10 Feb 1998
Urinary Tract Infections	United States	Sandoz, Inc.	10 Feb 1998

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis